Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX", effective September 23, 2024. The company will continue to trade on the Nasdaq Stock Market. Scienture Holdings, Inc., through its wholly owned subsidiaries Scienture and Integra Pharma Solutions, , is a comprehensive pharmaceutical product company focused on providing novel specialty products to meet unmet market needs.
The company's products are in development across various therapeutic areas and indications, catering to different market segments and channels. The executive team and board of directors consist of experienced industry veterans, including Suren Ajjarapu as CEO and Chairman, Prashant Patel as President, Interim CFO and COO, and other accomplished members.